<DOC>
	<DOCNO>NCT01484496</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety tolerability belimumab administer subcutaneously ( SC ) adult subject Systemic Lupus Erythematosus ( SLE ) .</brief_summary>
	<brief_title>A Study Belimumab Administered Subcutaneously Subjects With Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>This Phase 3 , multi-center , international , randomize , double-blind , placebo-controlled , 52-week study evaluate efficacy , safety tolerability belimumab administer subcutaneously ( SC ) ( 200 mg weekly ) adult subject active Systemic Lupus Erythematosus ( SLE ) . Approximately 816 SLE subject randomize , target 544 subject receive belimumab 272 subject receive placebo . Subjects complete 52-week double-blind period enter 6-month open-label extension subject receive belimumab 200 mg SC weekly .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>1 . At least 18 year age . 2 . Clinical diagnosis Systemic Lupus Erythematosus ( SLE ) ACR criterion . 3 . Active SLE disease . 4 . Autoantibodypositive . 5 . On stable SLE treatment regimen may include corticosteroid ( example , prednisone ) , antimalarial ( example , hydroxychloroquine ) and/or immunosuppressant ( example , azathioprine , methotrexate , mycophenolate , etc . ) 1 . Pregnant nursing . 2 . Have receive treatment B cell target therapy ( example , rituximab belimumab ) . 3 . Have receive treatment investigational biological agent past year . 4 . Have receive intravenous ( IV ) cyclophosphamide within 90 day Day 0 . 5 . Have severe active lupus kidney disease . 6 . Have severe active central nervous system ( CNS ) lupus . 7 . Have require management acute chronic infection within past 60 day . 8 . Have current drug alcohol abuse dependence . 9 . Have positive test human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C. 10 . Have history hypersensitivity reaction contrast agent biological medicine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Subcutaneous</keyword>
	<keyword>Lupus</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>SLE</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Antibodies</keyword>
</DOC>